检索结果共有:66,793
  • 1

    摘要: The Chinese Society of Hepatology developed the current guidelines on the management of hepatic encephalopathy in cirrhosis based on the published evidence and the panelists' consensus. The guidelines provided recommendations for the diagnosis and management of hepatic encephalopathy (HE) including minimal hepatic encephalopathy (MHE) and overt hepatic encephalopathy, emphasizing the importance on screening MHE in patients with end-stage liver diseases. The guidelines emphasized that early identification and timely treatment are the key to improve the prognosis of HE. The principles of treatment include prompt removal of the cause, recovery of acute neuropsychiatric abnormalities to baseline status, primary prevention, and secondary prevention as soon as possible.

    文献发表年:2019 文献期刊: World J Gastroenterol 所属领域:抗突发性传染病药物研发 所属分类: 指南法规 / 中国
  • 2

    摘要: The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

    文献发表年:2016 文献期刊: Clin Pharmacol Ther 所属领域:抗突发性传染病药物研发 所属分类: 指南法规 / 中国
  • 3

    摘要: The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed, including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.

    文献发表年:2020 文献期刊: Int J Infect Dis 所属领域:抗突发性传染病药物研发 所属分类: 指南法规 / 中国
  • 4

    摘要: The European Association for the Study of the Liver recently released the updated Clinical Practice Guidelines on the management of hepatitis B virus infection at the International Liver Congress(TM) 2017 in Amsterdam. The latest clinical practice guideline integrated the latest scientific advances on diagnosis and therapy of hepatitis B, thereby providing optimize the management of patients with either acute or chronic HBV. The latest clinical practice guideline includes new definitions of disease phases, expanded indications for initiating treatment, prevention of mother-to-child transmission, new stopping rules for antiviral therapy. Future treatment strategies to achieve 'cure' of disease and new biomarkers are discussed.

    文献发表年:2017 文献期刊: Zhonghua Gan Zang Bing Za Zhi 所属领域:抗突发性传染病药物研发 所属分类: 指南法规 / 中国
  • 5

    摘要: The International Summit on Laparoscopic Pancreatic Resection (ISLPR) was held in Coimbatore, India, on 7th and 8th of October 2016 and thirty international experts who regularly perform laparoscopic pancreatic resections participated in ISPLR from four continents, i.e., South and North America, Europe and Asia. Prior to ISLPR, the first conversation among the experts was made online on August 26th, 2016 and the structures of ISPLR were developed. The aims of ISPLR were; i) to identify indications and optimal case selection criteria for minimally invasive pancreatic resection (MIPR) in the setting of both benign and malignant diseases; ii) standardization of techniques to increase the safety of MIPR; iii) identification of common problems faced during MIPR and developing associated management strategies; iv) development of clinical protocols to allow early identification of complications and develop the accompanying management plan to minimize morbidity and mortality. As a process for interactive discussion, the experts were requested to complete an online questionnaire consisting of 65 questions about the various technical aspects of laparoscopic pancreatic resections. Two further web-based meetings were conducted prior to ISPLR. Through further discussion during ISPLR, we have created productive statements regarding the topics of Disease, Implementation, Patients, Techniques, and Instrumentations (DIPTI) and hereby publish them as "Coimbatore Summit Statements".

    文献发表年:2018 文献期刊: Surg Oncol 所属领域:抗突发性传染病药物研发 所属分类: 指南法规 / 中国
  • 6

    摘要: The key points from the updated guideline of prevention and treatment for hepatitis C (2019 version) is compared with the previous hepatitis C guideline. A new terminology and the World Health Organization's goal of eliminating viral hepatitis as a public-health threat by 2030 are stressed. In the prevention section, the screening for hepatitis C virus infection in high-risk population is the primary means of prevention, emphasizing that treatment, is prevention. In the aspect of treatment, pangenotypic interferon-free scheme are initial recommendations. In addition, it also introduces our country independent research and development on direct-acting antiviral agents, and antiviral therapy schedule for many special populations, including decompensated liver cirrhosis, chronic kidney disease, children and adolescents combined with chronic kidney injury, HBV infection-before and after liver transplantation, treatment failure, and acute hepatitis C. A simplified on-treatment monitoring schedule, especially genotype 3 prevalent in Southwest part of our country is introduced.

    文献发表年:2020 文献期刊: Zhonghua Gan Zang Bing Za Zhi 所属领域:抗突发性传染病药物研发 所属分类: 指南法规 / 中国
  • 7

    摘要: The link between chronic kidney disease (CKD) and tuberculosis (TB) has been known for more than 40 years, but the interaction between these 2 diseases is still poorly?understood. Dialysis and renal transplant patients?appear to be at a higher risk of TB, in part related?to immunosuppression along with socioeconomic, demographic, and comorbid factors. Meanwhile, TB screening and diagnostic test performance is suboptimal in?the CKD population, and there is limited evidence to guide protocols. Given the increasing prevalence of CKD in?TB endemic areas, a merging of CKD and TB epidemics could have significant public health implications, especially in low- to middle-income countries such as India and China,?that are experiencing rapid increases in CKD prevalence and account for more than one-third of global?TB prevalence. To begin addressing TB-CKD, a clear?understanding of the relationship between these 2?conditions needs to be established, and consistent, evidence-based screening and treatment guidelines need to be developed.

    文献发表年:2016 文献期刊: Kidney Int 所属领域:抗突发性传染病药物研发 所属分类: 指南法规 / 中国
  • 8

    摘要: The mechanisms of idiopathic pulmonary fibrosis (IPF), a rare, devastating disease with a median survival of 3-5 years, are not fully understood. Gastroesophageal reflux disease (GERD) is a frequent comorbidity encountered in IPF. Hypothetically, GERD-associated microaspiration may lead to persistent inflammation impairing lung infrastructure, thereby possibly accelerating the progression of IPF. IPF may increase intrathoracic pressure, which can aggravate GERD and vice versa. On the basis of the possible beneficial effects of antireflux or antacid therapy on lung function, acute exacerbation, and survival, the recent international IPF guideline recommends antacid therapies for patients with IPF, regardless of symptomatic GERD. However, due to newer conflicting data, several national guidelines do not support this recommendation. Elucidation of these questions by further clinical and bench-to-bedside research may provide us with rational clinical diagnostic and therapeutic approaches concerning GERD in IPF. The present review aims to discuss the latest data on the controversial association of IPF and GERD.

    文献发表年:2018 文献期刊: Respiration 所属领域:抗突发性传染病药物研发 所属分类: 指南法规 / 中国
  • 9

    摘要: The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYSICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers).

    文献发表年:2014 文献期刊: Eur Respir J 所属领域:抗突发性传染病药物研发 所属分类: 指南法规 / 中国
  • 10

    摘要: The outbreak caused by SARS-CoV-2 beta-coronavirus, first identified in Wuhan, China, was declared a pandemic by the World Health Organization on 11th March, 2020. In Hungary, the first confirmed COVID-19 case was reported on 4th March, 2020, and on 15th March, the first fatality related to the infection was announced. At the moment of the latter event, there was no central, standardized guideline, which could explain the necessary precautions, and provide an unequivocal description on how to handle the dead body. The procedure of transportation, storage, occurent autopsy or final disposition of the deceased raise a lot of questions, especially on how to carry out these tasks. Legislation related to infectious diseases and decedent management in general do not provide enough information on how to perform duties in a COVID-19 fatality case. The chief medical officer suspended the execution of autopsies, except in cases of unnatural death, since 19th March, however, the transportation and storage of fatalities can still be a problem. The Department of Pathology of the Healthcare Professional College of the Ministry of Human capacities published a procedure on recommended post-mortem duties on 21st March, but the suggested protocols only represent a narrow spectrum of international recommendations. Therefore supplementation may be necessary. Sadly, post-mortem protocols, in spite of their importance, are also underrepresented in the international literature. A further problem, wich makes adoptability difficult, is that available foreign guidelines and algorithms are optimized for different legislation, and organisations, resources not available in our country. In this article, besides providing a summary of literature, we would also like to make practical recommendations which may increase the safety of healthcare providers participating in the treatment or pathological duties with COVID-19 suspected, probable and confirmed cases. Orv Hetil. 2020; 161(17): 713–722.

    文献发表年:2020 文献期刊: Orv Hetil 所属领域:抗突发性传染病药物研发 所属分类: 指南法规 / 中国
共有结果信息66,793条,每页10条 1 2 3 >

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190